2021 Rare Disease Day

February 26, 2021 10:00 AM - 12:30 PM

Online Conference, Link will be sent in advance of the event.

Add to Calendar 2/26/2021 10:00:00 AM 2/26/2021 12:30:00 PM 2021 Rare Disease Day MassBio’s Rare Disease Day recognizes the research being done in Massachusetts to treat and cure rare disease. The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases, which affect nearly 30 million Americans and countless others around the world.

This year’s program will focus on how we can better address health inequity and racial disparities among the rare disease community. Attendees will hear an inspiring Possible Talk, an insightful panel of industry, physicians, patients/caregivers, and advocates, and a closing patient keynote. Ample networking time will be provided (virtually!).

Alone we are rare, together we are strong. 

To inquire about sponsorship opportunities, contact Laura Rudberg.

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning. Online Conference, Link will be sent in advance of the event.
Sr. Director Clinical Operations, Biogen
Desiree has over 20 years working in clinical research and the pharma/biotech industry. She holds an MPH from Boston University where she focused on work in Health Disparities and Epidemiology. Desiree received an undergraduate degree in Psychology from the University of Pennsylvania. Currently as a member of the senior leadership team in Biogen’s Clinical Operations group, Desiree has led diverse portfolios across multiple disease units including Movement Disorders, Pain, Ophthalmology and Neuromuscular Diseases. She has successfully managed multiple programs in diseases with rare populations including ALS, Ataxias, Retinal Disorders and Cystic Fibrosis. She led two of the original Vertex Pharmaceuticals cystic fibrosis programs, Kalydeco and Orkambi, that resulted in marketed approvals. Desiree is keenly interested in clinical trials innovations that advance development to enable treatments to patients with rare and life- threatening diseases.

Brought to you by